Search Result

Results for "

Huntington

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Amyloid-β (1) Apoptosis (4) Atg8/LC3 (2) ATTECs (2) Autophagy (6) Calcium Channel (2) Caspase (4) DNA/RNA Synthesis (1) Drug Metabolite (1) DYRK (1) Endogenous Metabolite (1) Glutaminase (3) Glutathione Reductase (1) HDAC (2) Huntingtin (7) Isotope-Labeled Compounds (2) Mitochondrial Metabolism (1) Monoamine Transporter (6) P-glycoprotein (1) Parasite (1) PERK (1) ROCK (1) Sirtuin (5) Tau Protein (1) TRP Channel (1) α-synuclein (1)
By Research Areas:	Cancer (4) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (42)

By Targets:

AMPK (1)

Amyloid-β (1)

Apoptosis (4)

Atg8/LC3 (2)

ATTECs (2)

Autophagy (6)

Calcium Channel (2)

Caspase (4)

DNA/RNA Synthesis (1)

Drug Metabolite (1)

DYRK (1)

Endogenous Metabolite (1)

Glutaminase (3)

Glutathione Reductase (1)

HDAC (2)

Huntingtin (7)

Isotope-Labeled Compounds (2)

Mitochondrial Metabolism (1)

Monoamine Transporter (6)

P-glycoprotein (1)

Parasite (1)

PERK (1)

ROCK (1)

Sirtuin (5)

Tau Protein (1)

TRP Channel (1)

α-synuclein (1)

By Research Areas:

Cancer (4)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (42)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147060

Dyrk1A-IN-3	DYRK	Neurological Disease
Dyrk1A-IN-3 (Compound 8b), a highly selective dual-specificity tyrosine-regulated kinase 1A (DYRK1A) inhibitor, maintains high levels of DYRK1A binding affinity (IC₅₀=76 nM). Dyrk1A-IN-3 can be used for the research of neurodegenerative disorders such as Alzheimer’s Disease, Huntington’s Disease, and Parkinson’s Disease .

HY-108312A

AC-VEID-CHO TFA	Caspase	Neurological Disease
AC-VEID-CHO (TFA) is a peptide-derived caspase inhibitor and has potency of inhibition for Caspase-6, Caspase-3 and Caspase-7 with IC₅₀ values of 16.2 nM, 13.6 nM and 162.1 nM, respectively. AC-VEID-CHO (TFA) can be used for the research of neurodegenerative conditions including Alzheimer’s and Huntington’s disease .

HY-W019710

(E,E)-RGFP966

HDAC Neurological Disease

(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

(E,E)-RGFP966	HDAC	Neurological Disease
(E,E)-RGFP966 is a selective and CNS permeable HDAC3 inhibitor that can be used for the research of Huntington’s disease .

HY-132593

Rovanersen WVE-120101	Huntingtin	Neurological Disease
Rovanersen (WVE-120101) is an antisense oligonucleotide that specifically targets mutated mRNA copies of the huntington (HTT) gene without affecting healthy mRNA of HTT gene, thereby preventing the production of faulty Huntingtin protein. Rovanersen can be used for huntington’s disease research .

HY-122958

Peucedanocoumarin III	α-synuclein	Neurological Disease
Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

HY-107660

SIRT2-IN-8

Sirtuin Neurological Disease

SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .

SIRT2-IN-8	Sirtuin	Neurological Disease
SIRT2-IN-8 is a potent SIRT2 inhibitor. SIRT2-IN-8 can be used for Huntington’s and Parkinson’s diseases research .

HY-137207

MK-28 3 Publications Verification	PERK	Neurological Disease
MK-28 is a potent and selective PERK activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .

HY-132594A

Lexanersen sodium

WVE-120102 sodium
Huntingtin Neurological Disease

Lexanersen sodium is an antisense oligonucleotide used for the study of Huntington's disease .
HY-156650

Votoplam

DNA/RNA Synthesis Neurological Disease

Votoplam is a gene splicing modulator, used to inhibit Huntington's disease .

Lexanersen sodium WVE-120102 sodium	Huntingtin	Neurological Disease
Lexanersen sodium is an antisense oligonucleotide used for the study of Huntington's disease .

Votoplam	DNA/RNA Synthesis	Neurological Disease
Votoplam is a gene splicing modulator, used to inhibit Huntington's disease .

HY-15262

SRT 2104 10+ Cited Publications	Sirtuin	Neurological Disease Metabolic Disease Cancer
SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD ⁺ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease .

HY-G0025

Tetrabenazine Metabolite (-)-β-Dihydrotetrabenazine; (-)-β-HTBZ	Monoamine Transporter Drug Metabolite	Neurological Disease
Tetrabenazine Metabolite is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite is a vesicular monoamine transporter 2 (VMAT2) inhibitor with a high affinity (K_i=13.4 nM) . Tetrabenazine Metabolite is be developed for the treatment of chorea associated with Huntington’s disease and other hyperkinetic disorders .

HY-132594

Lexanersen

WVE-120102
Huntingtin Neurological Disease

Lexanersen (WVE-120102) is an antisense oligonucleotide used for the study of Huntington's disease .

Lexanersen WVE-120102	Huntingtin	Neurological Disease
Lexanersen (WVE-120102) is an antisense oligonucleotide used for the study of Huntington's disease .

HY-150640

Rho-Kinase-IN-2	ROCK	Neurological Disease
Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC₅₀=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .

HY-47822

WAY-354574

Sirtuin Neurological Disease

WAY-354574 is an active molecule targeting deacetylase (Sirtuin) for the study of Huntington's disease (HD) .

WAY-354574	Sirtuin	Neurological Disease
WAY-354574 is an active molecule targeting deacetylase (Sirtuin) for the study of Huntington's disease (HD) .

HY-132579

Tominersen RG6042; IONIS-HTTRx	Huntingtin	Neurological Disease
Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD) .

HY-134145

1-(Anilinocarbonyl)proline

Others Neurological Disease

1-(Anilinocarbonyl)proline can be used to identify dual action probes in a cell model of Huntington .

1-(Anilinocarbonyl)proline	Others	Neurological Disease
1-(Anilinocarbonyl)proline can be used to identify dual action probes in a cell model of Huntington .

HY-150236

FITC-labeled Tominersen sodium	Huntingtin	Neurological Disease
FITC-labeled Tominersen (sodium) is the Tominersen labeled with FITC. Tominersen (RG6042) is a second-generation 2′-O-(2-methoxyethyl) antisense oligonucleotide that targets huntingtin protein (HTT) mRNA and potently suppresses HTT production. Tominersen improves survival and reduces brain atrophy in mice. Tominersen can be used for the research of Huntington’s disease (HD).

HY-143218

TPE-MI 1 Publications Verification Tetraphenylethene maleimide	Huntingtin Parasite	Neurological Disease
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells. TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .

HY-136311

NCT-504

Others Neurological Disease

NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC₅₀ of 15.8 μM. NCT-504 is potential for the research of Huntington's disease .
HY-147233

MIND4-19

Sirtuin Neurological Disease

MIND4-19 is a potent SIRT2 inhibitor with an IC₅₀ value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease .
HY-136833

X5050

Others Neurological Disease

X5050 is a REST inhibitor, with an EC₅₀ of 2.1 μM .

NCT-504	Others	Neurological Disease
NCT-504 is a selective allosteric inhibitor of PIP4Kγ, with an IC₅₀ of 15.8 μM. NCT-504 is potential for the research of Huntington's disease .

MIND4-19	Sirtuin	Neurological Disease
MIND4-19 is a potent SIRT2 inhibitor with an IC₅₀ value of 7.0 μM. MIND4-19 can be used for researching Huntington's disease .

X5050	Others	Neurological Disease
X5050 is a REST inhibitor, with an EC₅₀ of 2.1 μM .

HY-B0590S

Tetrabenazine-d6 Ro 1-9569-d₆	Monoamine Transporter	Neurological Disease
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590), is the first deuterium approved worldwide for the research of Huntington's disease, or other hyperkinetic movement disorders .

HY-15452

Selisistat Maximum Cited Publications 167 Publications Verification EX-527	Sirtuin	Inflammation/Immunology Cancer
Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC₅₀ of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease .

HY-B0590

Tetrabenazine Ro 1-9569	Monoamine Transporter	Neurological Disease
Tetrabenazine (Ro 1-9569) is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the K_d value of 1.34 nM. Tetrabenazine can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .

HY-B0590E

Tetrabenazine mesylate Ro 1-9569 mesylate	Monoamine Transporter	Neurological Disease
Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the K_d value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease .

HY-161163

IND 1316	AMPK	Neurological Disease
IND 1316 is an orally active, blood-brain barrier permeable AMPK activator with neuroprotective effects in animal models of Huntington's disease. IND 1316 can be used for research on neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease .

HY-16771

Valbenazine 2 Publications Verification NBI-98854	Monoamine Transporter	Neurological Disease
Valbenazine (NBI-98854) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the K_i of 110-190 nM .

HY-16771A

Valbenazine tosylate NBI-98854 tosylate	Monoamine Transporter	Neurological Disease
Valbenazine tosylate (NBI-98854 tosylate) is a vesicular monoamine transporter 2 (VMAT2) inhibitor with the K_i of 110-190 nM .

HY-N2099

Onjisaponin B	Autophagy	Neurological Disease
Onjisaponin B is a natural product derived from Polygala tenuifolia. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells, and exbibits potential therapeutic effects on Parkinson disease and Huntington disease .

HY-150245

mHTT-IN-1	Huntingtin	Neurological Disease
mHTT-IN-1 (Example 1) is a potent mutant huntingtin (mHTT) inhibitor. mHTT is toxic and a major cause of the inherited autosomal dominant neurodegenerative disorder, Huntington's disease (HD). mHTT-IN-1 conducts the reduction of mHTT with an EC₅₀ value of 46 nM .

HY-147260B

(Rac)-Dalzanemdor (Rac)-SAGE-718	TRP Channel	Neurological Disease
(Rac)-Dalzanemdor ((Rac)-SAGE-718) is an isomer of Dalzanemdor (HY-147260). Dalzanemdor is an orally active and highly intrinsically active N-methyl-d-aspartate receptor (NMDAR)-positive allosteric modulator (PAM). Dalzanemdor can be used in the research of Huntington's disease .

HY-153427

Tau protein aggregation-IN-1	Tau Protein	Neurological Disease
Tau protein aggregation-IN-1 (Compound 0c) is a Tau protein aggregation inhibitor. Tau protein aggregation-IN-1 can be used in the study of protein folding disorders such as Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease and prion-based spongiform encephalopathies .

HY-124476

Cystamine	Caspase Glutaminase Apoptosis	Cancer
Cystamine is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .

HY-W020050

Cystamine (dihydrochloride）	Caspase Glutaminase Apoptosis	Neurological Disease Cancer
Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC₅₀ value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD) .

HY-128477

AUTEN-67 inner salt Autophagy enhancer-67 inner salt	Autophagy	Neurological Disease
AUTEN-67 (inner salt), the inner salt form of AUTEN-67 (HY-117924), is an orally active autophagy-enhancing agent and MTMR14 inhibitor with potent antiaging and neuroprotective effects. AUTEN-67 (inner salt) hampers the progression of neurodegenerative symptoms in a drosophila model of Huntington's disease .

HY-16482

Teglicar	Endogenous Metabolite	Neurological Disease Metabolic Disease
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC₅₀ value of 0.68 μM and a K_i value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .

HY-B1899

Taurodeoxycholic acid
Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .

HY-12542

Dantrolene 5+ Cited Publications F 368	Calcium Channel Autophagy	Neurological Disease Inflammation/Immunology
Dantrolene is an orally active, non-competitive glutathione reductase inhibitor with a K_i of 111.6 μM and an IC₅₀ of 52.3 μM. Dantrolene is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene is a direct-acting skeletal muscle relaxant. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome .

HY-143792

HTT-D3	P-glycoprotein	Neurological Disease
HTT-D3 is a potent and orally active huntingtin (HTT) splicing modulator. HTT-D3 acts by promoting the inclusion of a pseudoexon containing a premature termination codon (stop-codon psiExon), leading to HTT mRNA degradation and reduction of HTT levels. HTT-D3 reduces p-glycoprotein (P-gp) efflux, and can be uesd for Huntington's disease research .

HY-136780

SEN177	Amyloid-β	Neurological Disease
SEN177 is a potent glutaminyl cyclase (QPCT) inhibitor with an IC₅₀ of 0.013μM for glutaminyl-peptide cyclotransferase-like (QPCTL). SEN177 has a K_i of 20 nM for human glutaminyl cyclase (hQC). SEN177 greatly reduces the early stages of mutant HTT oligomerisation and reduces the percentage of neurons with Q80 aggregates. SEN177 has the potential for Huntington’s disease research .

HY-W020050S

Cystamine-d8 (dihydrochloride）	Apoptosis Caspase Glutaminase
Cystamine-d₈ (dihydrochloride） is the deuterium labeled Cystamine (dihydrochloride）[1]. Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD)[2][3][4].

HY-12542A

Dantrolene sodium hemiheptahydrate 5+ Cited Publications Dantrolene sodium hydrate	Calcium Channel Autophagy	Others
Dantrolene sodium hemiheptahydrate is an orally active, non-competitive glutathione reductase inhibitor with a K_i of 111.6 μM and an IC₅₀ of 52.3 μM. Dantrolene sodium hemiheptahydrate is a ryanodine receptor (RyR) antagonist and Ca2+ signaling stabilizer. Dantrolene sodium hemiheptahydrate is a direct-acting skeletal muscle relaxant. Dantrolene sodium hemiheptahydrate can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome .

HY-100384

NKL 22 1 Publications Verification	HDAC	Neurological Disease
NKL 22 (compound 4b) is a potent and selective inhibitor of histone deacetylases (HDAC), with an IC₅₀ of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 exhibits selectivity over HDAC2/4/5/7/8 (IC₅₀≥1.59 μM). NKL 22 ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice .

HY-12542S

Dantrolene-13C3 F 368-¹³C₃	Isotope-Labeled Compounds Glutathione Reductase	Neurological Disease Inflammation/Immunology
Dantrolene- ¹³C₃ is the ¹³C₃ labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

HY-130258

LC3-mHTT-IN-AN1	Atg8/LC3 ATTECs Autophagy	Neurological Disease
LC3-mHTT-IN-AN1 (Compound AN1) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN1 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .

HY-130259

LC3-mHTT-IN-AN2	Atg8/LC3 ATTECs Autophagy	Neurological Disease
LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN2 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .

HY-B1899S

Taurodeoxycholic acid-d5	Isotope-Labeled Compounds	Others
Taurodeoxycholic acid-d₅is the deuterium labeledTaurodeoxycholic acid(HY-B1899) . Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .

HY-N0303

Idebenone 3 Publications Verification	Mitochondrial Metabolism Apoptosis	Neurological Disease
Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC₅₀=16.65 μM) . Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells . Idebenone quickly crosses the blood-brain barrier.

Cat. No.	Product Name

HY-L086

Neurodegenerative Disease-related Compound Library

2221 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2221 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L003

Apoptosis Compound Library

2211 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 2211 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2099

Onjisaponin B	Triterpenes Neurological Disease Classification of Application Fields Terpenoids Source classification Polygalaceae Plants Disease Research Fields Polygala tenuifolia Willd.	Autophagy
Onjisaponin B is a natural product derived from Polygala tenuifolia. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin in PC-12 cells, and exbibits potential therapeutic effects on Parkinson disease and Huntington disease .

HY-16482

Teglicar	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
Teglicar is a selective and reversible orally active liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1) inhibitor with an IC₅₀ value of 0.68 μM and a K_i value of 0.36 μM. Teglicar has a potential antihyperglycemic propert. Teglicar can be used for the research of diabetes and neurodegenerative disease including Huntington's disease (HD) .

HY-130259

LC3-mHTT-IN-AN2	Structural Classification other families Source classification Coumarins Phenols Polyphenols Phenylpropanoids Plants	Atg8/LC3 ATTECs Autophagy
LC3-mHTT-IN-AN2 (Compound AN2) is a mHTT-LC3 linker compound, which interacts with both mutant huntingtin protein (mHTT) and LC3B but not with wtHTT or irrelevant control proteins. LC3-mHTT-IN-AN2 reduces the levels of mHTT in an allele-selective manner in cultured Huntington disease (HD) mouse neurons .

HY-122958

Peucedanocoumarin III	Structural Classification Source classification Isodon yuennanensis (Handel-Mazzetti) H. Hara Coumarins Phenylpropanoids Plants Umbelliferae	α-synuclein
Peucedanocoumarin III is an inhibitor of α-synuclein and Huntington protein aggregates that enhances the clearance of nuclear and cytoplasmic β23 aggregates and prevents cytotoxicity induced by disease-associated proteins (i.e., mutant Huntington proteins and α-synuclein). Peucedanocoumarin III may be used in Parkinson's disease research .

Cat. No.	Product Name	Chemical Structure

HY-B0590S

Tetrabenazine-d6
Tetrabenazine-d₆ (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590), is the first deuterium approved worldwide for the research of Huntington's disease, or other hyperkinetic movement disorders .

HY-B1899S

Taurodeoxycholic acid-d5

Taurodeoxycholic acid-d₅is the deuterium labeledTaurodeoxycholic acid(HY-B1899) . Taurodeoxycholic acid, a bile acid, stabilizes the mitochondrial membrane, decreases free radical formation. Taurodeoxycholic acid inhibits apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurodeoxycholic acid exhibits neuroprotective effect in 3-nitropropionic acid induced mouse model or genetic mouse model of Huntington's disease (HD) .

HY-W020050S

Cystamine-d8 (dihydrochloride）

Cystamine-d₈ (dihydrochloride） is the deuterium labeled Cystamine (dihydrochloride）[1]. Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD)[2][3][4].

HY-12542S

Dantrolene-13C3

Dantrolene- ¹³C₃ is the ¹³C₃ labeled Dantrolene. Dantrolene (F368), a muscle relaxant, non-competitively inhibits human erythrocyte glutathione reductase. Ki and IC50 values are 111.6 μM and 52.3 μM, respectively. Dantrolene is a ryanodine receptor antagonist and Ca2+ signaling stabilizer. Dantrolene can be used for the research of muscle spasticity, malignant hyperthermia, Huntington's disease and other neuroleptic malignant syndrome.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks